Literature DB >> 380909

A double-blind controlled trial of amineptine versus trimipramine in depression.

C Vauterin, M Bazot.   

Abstract

A double-blind controlled trial was carried out in 50 depressed out-patients to compare the effectiveness and tolerability of amineptine (200 mg per day) with that of trimipramine (75 mg per day). Patients were allocated at random to receive one or other of the trial drugs over a period of 45 days. Assessments were made before, during and after treatment of a number of target symptom clusters. Whilst overall response to treatment was the same with both drugs, trimipramine was superior in those patients presenting with anxiety and insomnia. Amineptine, however, was more effective not only against depressive mood and psychomotor retardation, but also against loss of libido, hypochondriacal features and social withdrawal. Both drugs were relatively well tolerated, but trimipramine had a sedative effect which proved troublesome in some patients.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 380909     DOI: 10.1185/03007997909109405

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  3 in total

1.  Chronopharmacokinetic and bioequivalence studies of two formulations of trimipramine after oral administration in man.

Authors:  A M Bougerolle; J L Chabard; M Jbilou; G Dordain; A Eschalier; O Aumaitre; J Gaillot; J J Piron; J Petit; J A Berger
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Apr-Jun       Impact factor: 2.441

Review 2.  Antidepressant drugs and the emergence of suicidal tendencies.

Authors:  M H Teicher; C A Glod; J O Cole
Journal:  Drug Saf       Date:  1993-03       Impact factor: 5.606

3.  Prefrontal cortical control of a brainstem social behavior circuit.

Authors:  Tamara B Franklin; Bianca A Silva; Zinaida Perova; Livia Marrone; Maria E Masferrer; Yang Zhan; Angie Kaplan; Louise Greetham; Violaine Verrechia; Andreas Halman; Sara Pagella; Alexei L Vyssotski; Anna Illarionova; Valery Grinevich; Tiago Branco; Cornelius T Gross
Journal:  Nat Neurosci       Date:  2017-01-09       Impact factor: 24.884

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.